DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 1 USDMF, 1 Listed Suppliers

2 API Suppliers
1 USDMF
1 Listed Suppliers

DEVELOPMENTS

17 Drugs in Development

17 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

DIGITAL CONTENT

1 STOCK RECAP #PipelineProspector, 4 NEWS #PharmaBuzz

media
1 STOCK RECAP #PipelineProspector
4 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 195733-43-8, Atrasentan hcl, Atrasentan (hydrochloride), Atrasentan hydrochloride [usan], Abbot-147627, E4g31x93za

Molecular Formula

C₂₉H₃₉ClN₂O₆

Molecular Weight

547.1 g/mol

InChI Key

IJFUJIFSUKPWCZ-SQMFDTLJSA-N

FDA UNII

E4G31X93ZA

A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.

1 2D Structure

Atrasentan

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid;hydrochloride

2.1.2 InChI

InChI=1S/C29H38N2O6.ClH/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20;/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34);1H/t23-,27-,28+;/m1./s1

2.1.3 InChI Key

IJFUJIFSUKPWCZ-SQMFDTLJSA-N

2.1.4 Canonical SMILES

CCCCN(CCCC)C(=O)CN1CC(C(C1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4.Cl

2.1.5 Isomeric SMILES

CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4.Cl

2.2 Other Identifiers

2.2.1 UNII

E4G31X93ZA

2.3 Synonyms

2.3.1 MeSH Synonyms

1. (11c)abt-627

2. 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic Acid

3. A 127722

4. A 127722.5

5. A 147627

6. A-127722

7. A-127722.5

8. A-147627

9. A127722

10. A127722.5

11. A147627

12. Abt 627

13. Abt-627

14. Abt627

15. Atrasentan

16. Xinlay

2.3.2 Depositor-Supplied Synonyms

1. 195733-43-8

2. Atrasentan Hcl

3. Atrasentan (hydrochloride)

4. Atrasentan Hydrochloride [usan]

5. Abbot-147627

6. E4g31x93za

7. 3-pyrrolidinecarboxylicacid,4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-,hydrochloride (1:1), (2r,3r,4s)-

8. 195733-43-8 (hcl)

9. A-147627.1

10. Atrasentan Hydrochloride (usan)

11. Abbott 147627

12. Unii-e4g31x93za

13. (2r,3r,4s)-1-((dibutylcarbamoyl)methyl)-2-(p-methoxyphenyl)-4-(3,4-(methylenedioxy)phenyl)-3-pyrrolidinecarboxylic Acid, Monohydrochloride

14. (2r,3r,4s)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic Acid Hydrochloride

15. (2r,3r,4s)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic Acid Hydrochloride.

16. A 147627.1

17. D03009

18. (2r,3r,4s)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic Acid Hydrochloride

19. Chembl2106068

20. Dtxsid20173240

21. Ex-a4175

22. Atrasentan Hydrochloride [mi]

23. Hy-15403a

24. Mfcd13194884

25. Cs-1373

26. Atrasentan Hydrochloride [mart.]

27. Atrasentan Hydrochloride [who-dd]

28. Bs-16407

29. Atrasentan Hydrochloride, >=98% (hplc)

30. D82853

31. 733a438

32. A930316

33. Abt-627;abt627;abt 627;abbott 147627

34. Q27276859

35. (2r,3r,4s)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(n,n-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic Acid Hydrochloride Salt

36. (2r,3r,4s)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic Acid;hydrochloride

37. (2r,3r,4s)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylicacidhydrochloride

38. 3-pyrrolidinecarboxylic Acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, Monohydrochloride, (2r,3r,4s)-

39. 3-pyrrolidinecarboxylic Acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, Monohydrochloride, (2r-(2.alpha.,3.beta.,4.alpha.))

40. 3-pyrrolidinecarboxylic Acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, Monohydrochloride, (2r-(2alpha,3beta,4alpha))

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₂₉H₃₉ClN₂O₆
Molecular Weight	547.1 g/mol
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	12
Exact Mass	546.2496647 g/mol
Monoisotopic Mass	546.2496647 g/mol
Topological Polar Surface Area	88.5 Å²
Heavy Atom Count	38
Formal Charge	0
Complexity	734
Isotope Atom Count	0
Defined Atom Stereocenter Count	3
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

Treatment of nephropathy

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

Endothelin A Receptor Antagonists

Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN A RECECPTORS. (See all compounds classified as Endothelin A Receptor Antagonists.)

API SUPPLIERS